The Treatment of Childhood and Adolescent Obesity

Armstrong, Sarah; Farpour‐Lambert, Nathalie

doi:10.1002/9781119695257.ch27

Cited by 1 publication

(2 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…60 Future potential pharmacotherapies predominantly target bile acid signalling, insulin resistance and lipid handling within the liver. 61…”

Section: Prevalence and Risk Factors For Nash/fibrosismentioning

confidence: 99%

See 1 more Smart Citation

Review of paediatric obesity and non‐alcoholic fatty liver disease—A focus on emerging non‐pharmacologic treatment strategies

Piester,

Jagtap,

Kalapala

2023

Pediatric Obesity

View full text Add to dashboard Cite

SummaryObesity in paediatrics has become one of the most serious public health concerns worldwide. Paediatric obesity leads to increased adult obesity and is associated with several comorbidities, both physical and psychological. Within gastroenterology, non‐alcoholic fatty liver disease (NAFLD) is now the most common cause of paediatric liver disease and the most common cause of liver transplantation in young adults. Treatment for NAFLD largely focuses on treatment of obesity with weight loss strategies. Unfortunately, the traditional method of weight loss using multicomponent lifestyle modification (dietary changes, increased exercise and behavioural modification) has often led to disappointing results. In adult patients with obesity, treatment strategies have evolved to include bariatric surgery and, more recently, bariatric endoscopy. In paediatrics, the obesity and NAFLD epidemics will likely require this variety of treatment to address children in a personalized manner. Here, we present a review of paediatric obesity, paediatric NAFLD and the various treatment strategies to date. We focus on non‐pharmacologic and emerging therapies, including bariatric surgery and bariatric endoscopy‐based treatments. With such a large population of children and adolescents with obesity, further development of these treatments, including paediatric‐focused clinical trials, is essential for these emerging modalities.

show abstract

“…60 Future potential pharmacotherapies predominantly target bile acid signalling, insulin resistance and lipid handling within the liver. 61…”

Section: Prevalence and Risk Factors For Nash/fibrosismentioning

confidence: 99%

“…Pioglitazone has demonstrated effectiveness in resolving NASH, inflammation, and fibrosis but is associated with weight gain and increased risk of fractures 60 . Future potential pharmacotherapies predominantly target bile acid signalling, insulin resistance and lipid handling within the liver 61 …”

Section: Current Treatments For Obesity and Nafldmentioning

confidence: 99%